S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ALRN Aileron Therapeutics Inc

3.86

-0.30 (-7.21%)

Last Updated: 10:45:43

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Aileron Therapeutics Charts.

Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Aileron Therapeutics Charts.

Aileron Therapeutics Inc News

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Wednesday 1 May 2024 (1 day ago) • GlobeNewswire Inc.

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Wednesday 1 May 2024 (1 day ago) • GlobeNewswire Inc.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Monday 15 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Aileron Therapeutics Announces CEO Transition
Tuesday 12 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Thursday 15 February 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 13 February 2024 (3 months ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Monday 5 February 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Monday 5 February 2024 (3 months ago) • Edgar (US Regulatory)

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Thursday 1 February 2024 (3 months ago) • GlobeNewswire Inc.

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Wednesday 31 January 2024 (3 months ago) • Edgar (US Regulatory)

More Aileron Therapeutics Inc News Articles

Atacama Resources (PK)

Mullen Automotive

NaturalShrimp (QB)

Verb Technology

Global Developments (PK)

Moon Equity (PK)

BlackStar Enterprise (PK)

International Star (PK)

MicroCloud Hologram

Globestar Therapeutics (PK)

NioCorp Developments

Movement Industries (PK)

Branded Legacy (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions